HLA-C and neoplasm: Predictors of strong clinical response include higher density and tumor infiltration of cytotoxic CD8+ T-cells, higher expression of PD-L1 and major histocompatibility complex (MHC) molecules on tumor cells, increased tumor mutational burden or microsatellite instability, and enriched immune-related gene signatures (Giraldo et al., 2019; Rizk et al., 2020).